Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. director and co-founder Jonathan Sheena reported open-market sales of a total of 4,650 shares of common stock. The filing shows 2,175 shares sold indirectly by Caraluna 1 and Caraluna 2 trusts, for which Sheena disclaims beneficial ownership, and 2,475 shares sold from direct holdings.
Reported sale prices ranged from about $199 to $210.345 per share, with several trades reported at weighted average prices. Following the direct sales, Sheena’s directly held stake reported in this filing is 255,452 shares of Natera common stock, indicating these transactions represent a small portion of his reported holdings.
Footnotes state that both the May 8 and May 13 transactions were executed under pre-arranged Rule 10b5-1 trading plans, suggesting the sales were scheduled in advance rather than timed discretionarily.
Natera, Inc. reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Total revenues rose to $696.6 million from $501.8 million a year earlier, driven mainly by product revenues of $693.9 million.
The company recorded a net loss of $85.1 million, compared with a loss of $66.9 million in the prior-year quarter, as research and development plus selling, general and administrative expenses expanded. Basic and diluted net loss per share was $0.60 versus $0.50 a year ago.
Natera ended the period with $1.09 billion in cash, cash equivalents and restricted cash and generated $40.2 million of cash from operating activities. Total assets were $2.61 billion, including goodwill and intangible assets largely from the Foresight Diagnostics acquisition, while stockholders’ equity stood at $1.77 billion.
Natera, Inc. reported strong first quarter 2026 growth while remaining unprofitable. Total revenues rose to $696.6 million, up 38.8% from $501.8 million a year earlier, driven by higher test volume and better pricing. The company processed about 1,013,600 tests, including approximately 258,900 oncology tests, with clinical oncology volume up 54.4% year over year. Gross profit reached $450.8 million, giving a gross margin of 64.7%, slightly higher than 63.1% last year.
Total operating expenses increased to $538.6 million, largely from higher research and development and selling, general and administrative spending, including clinical trials and new product support. Natera posted a net loss of $85.1 million, or ($0.60) per diluted share, compared with a net loss of $66.9 million, or ($0.50) per share, in 2025. Cash, cash equivalents and restricted cash were $1,087.9 million as of March 31, 2026, slightly above $1,076.1 million at year-end 2025, and the company generated positive cash inflow of about $11.8 million in the quarter.
On the back of this performance, Natera raised its full-year 2026 revenue outlook from $2.62–$2.70 billion to $2.74–$2.82 billion and now expects gross margin around 64%–66%. Management highlighted record overall test volumes, strong women’s health growth supported by the Fetal Focus offering, and another record quarter in oncology testing, including momentum for its Signatera minimal residual disease test.
Natera, Inc. Executive Chairman Matthew Rabinowitz reported compensation-related stock activity. On May 5, 2026, he received 2,389 fully vested Restricted Stock Units (RSUs), each representing one share of common stock. Around the same time, he sold 7,708 shares of common stock in multiple open-market transactions at prices between $205.22 and $241.39.
According to the footnotes, these sales were executed to satisfy tax withholding and remittance obligations arising from RSU vesting and were carried out under written instructions intended to meet the affirmative defense conditions of Rule 10b5-1(c). After these transactions, he directly owned 2,378,791 shares of Natera common stock, with an additional 5,000 shares held indirectly by his spouse.
Natera, Inc. chief financial officer Michael Burkes Brophy reported selling a total of 795 shares of Common Stock in open-market transactions, including 313 shares at $206.16 on May 1, 2026 and 482 shares at $210.49 on May 4, 2026. According to the footnotes, these sales were carried out to satisfy tax withholding obligations related to vesting RSUs and were executed under written instructions and a Rule 10b5-1 trading plan. After these transactions, he directly holds 57,496 shares.
Natera, Inc. director and co-founder Jonathan Sheena reported a small sale of common stock tied to equity compensation. On the reported date, 107 shares were sold at $206.16 per share to satisfy tax withholding and remittance obligations related to vesting RSUs, under a written instruction intended to meet Rule 10b5-1(c) conditions. After this transaction, Sheena held 255,652 shares of Natera common stock directly. Separate trusts identified as Caraluna 1 Trust and Caraluna 2 Trust each held 20,282 shares for their beneficiaries, and Sheena disclaimed beneficial ownership of those trust-held shares.
Natera, Inc. executive Solomon Moshkevich, President of Clinical Diagnostics, sold a total of 3,405 shares of common stock on May 1, 2026 in multiple open-market transactions, at prices around $200–$207 per share.
According to the disclosures, part of the sale was made to satisfy tax withholding and remittance obligations tied to the vesting of restricted stock units, under written instructions intended to meet Rule 10b5-1(c) conditions. Additional shares were sold under a separate Rule 10b5-1 trading plan adopted on November 26, 2024. After these transactions, he directly holds 142,295 shares of Natera common stock.
Natera, Inc. president and chief business officer John Fesko reported an open-market sale of 291 shares of common stock at $206.16 per share. After the transaction, he directly held 187,220 shares. The footnote states the sale was made to cover tax withholding obligations from RSU vesting under a written instruction intended to satisfy Rule 10b5-1(c) conditions.
Natera, Inc. director and CEO Steven Leonard Chapman reported an open-market sale of 902 shares of Common Stock on May 1, 2026 at $206.16 per share. According to a footnote, the sale was made to satisfy tax withholding and remittance obligations tied to vesting RSUs under a pre-arranged instruction intended to meet Rule 10b5-1(c) conditions. After this transaction, he directly owned 149,867 shares of Natera common stock.
Natera, Inc. disclosed that its Secretary and Chief Legal Officer, Daniel Rabinowitz, executed an open-market sale of 330 shares of common stock on May 1, 2026 at $206.16 per share. After this transaction, he directly held 222,694 shares.
According to the footnote, the sale was made to cover tax withholding and remittance obligations related to the vesting of restricted stock units and was carried out under a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).